Canadian Pot Stocks to Watch Right Now
As cannabis markets shift this week, Canadian cannabis stocks are once again gaining investor attention. At the same time, the U.S. industry continues to grow rapidly. In 2024, legal cannabis sales in the U.S. reached nearly $39 billion. Projections suggest that the number could climb past $44 billion in 2025. Growth is expected to continue at a strong pace through the decade. Despite this momentum, federal legalization remains stalled. However, several U.S. states are pushing forward with their own reform efforts. This steady progress at the state level continues to attract interest. Canadian companies with U.S. exposure stand to benefit from this evolving landscape. As a result, watching top-performing Canadian cannabis stocks this week could reveal key breakout opportunities.
When evaluating these stocks, traders should lean on technical analysis and proper risk management. Look for momentum patterns and volume spikes to identify strong setups. Use moving averages to confirm short-term trends. Watch for support and resistance levels that guide entry points. Always set clear stop-losses before entering trades. This helps protect capital in fast-moving markets. Managing position size is just as important to avoid overexposure. Volatility in cannabis stocks remains high, so discipline is essential. News events can also act as catalysts and drive big price swings. Therefore, combining technical setups with solid risk controls is the best approach. With this strategy, investors can navigate the market more effectively while keeping downside risk in check.
North American Cannabis Industry Evolution
As the North American cannabis industry continues to evolve, Canadian companies are expanding their reach into the U.S. market. In July 2025, investors are focusing on companies that show solid revenue growth, expanding dispensary networks, and improving profit margins. Three Canadian cannabis companies stand out this month: Tilray Brands Inc. (TLRY), Canopy Growth Corporation (CGC), and Cronos Group Inc. (CRON). These companies are leveraging cross-border strategies to capitalize on the growing demand. Below is a closer look at each firm, including its U.S. presence and latest financial performance.
[Read More] 3 Marijuana Stocks For Long-Term Profits
3 Canadian Cannabis Stocks to Watch Amid U.S. Legalization News
- Tilray Brands Inc. (NASDAQ: TLRY)
- Canopy Growth Corporation (NASDAQ: CGC)
- Cronos Group Inc. (NASDAQ: CRON)
Tilray Brands Inc. (TLRY)
Tilray Brands is a well-known Canadian cannabis and consumer goods company. It has expanded heavily into the United States in recent years. Currently, it owns more than 150 dispensaries across multiple states. These include locations in key recreational markets like California and Michigan. Tilray also has a presence in the wellness and THC-infused beverage sector. It acquired several beverage brands to strengthen its U.S. portfolio. Additionally, it now ranks among the largest craft brewers in America. This diversification helps it compete across multiple cannabis-related verticals. As a result, Tilray aims to dominate in both product innovation and national distribution.
The company recently posted strong financial results for the quarter. Net revenue increased by 13%, reaching $200 million. Its cannabis segment generated $61 million with a 40% gross margin. The beverage segment showed notable growth, rising 132% year-over-year. Tilray’s gross profit also improved significantly, reaching nearly $60 million. This pushed its profit margins up by five percentage points. Although the company still posted a net loss, it narrowed that loss considerably. Adjusted EBITDA came in at $9 million. Tilray is working to streamline its product lines and cut underperforming SKUs. These moves are intended to focus growth in core areas. Overall, the financials point to improving fundamentals and operational efficiency.
[Read More] 3 Marijuana Stocks For Long-term Profits In The Cannabis Sector
Canopy Growth Corporation (CGC)
Canopy Growth remains one of the most recognized names in Canadian cannabis. It maintains a growing footprint in the United States. The company operates approximately 120 dispensaries across various U.S. states. These include both recreational and medical-use locations. Canopy also owns vaporizer company Storz & Bickel, which is popular with American consumers. Furthermore, it offers a variety of CBD products through U.S. partnerships. Over the past year, Canopy has focused on restructuring its operations. The company aims to cut costs and improve profitability. This strategy includes simplifying its supply chain and reducing its debt burden.
Canopy’s most recent quarterly report showed mixed results but highlighted progress. Net revenue came in at around C$66 million, down slightly from the previous year. However, gross profit rose by over 65%, signaling better cost control. The company achieved a 35% gross margin, which represents a significant improvement. Operating losses were also cut nearly in half, showing a clear path to financial health. Adjusted EBITDA loss narrowed to C$5 million, down significantly from the prior year. Additionally, Canopy cut its total debt by nearly 50% over the fiscal year. These financial improvements reflect a strong focus on long-term sustainability. With U.S. market expansion and leaner operations, Canopy Growth is regaining momentum.
[Read More] Best U.S. Cannabis Penny Stocks to Trade Now – July 2025 Watchlist
Cronos Group Inc. (CRON)
Cronos Group is a Toronto-based cannabis producer with a growing presence in the U.S. market. It has distribution deals across several states and currently supplies products to around 80 dispensaries. Cronos focuses heavily on cannabinoid innovation. This includes oils, vapes, and infused products tailored for wellness and recreational use. The company also works closely with U.S. retailers to distribute vaporizer products. Cronos is known for its science-driven approach. It continues to develop new formulations that appeal to both medical and lifestyle consumers. This targeted strategy has allowed Cronos to gain a foothold in high-margin product categories.
Financially, Cronos reported a solid quarter of growth. Net revenue reached over $32 million, reflecting a year-over-year gain. Gross profit also rose sharply, jumping to $13.7 million. This improvement was driven by better cost management and favorable product mix. The company is also seeing benefits from scaling its U.S. distribution channels. While full profitability has not yet been reached, Cronos is trending in the right direction. Management continues to invest in research and development. These investments are designed to position the company for long-term success in the competitive U.S. market. As consumer demand for quality cannabinoid products rises, Cronos appears well-positioned.
[Read More] Here’s How To Invest In Marijuana Stocks While The Sector Recovers
Canadian Marijuana Stocks for U.S. Growth Potential in July 2025
Tilray, Canopy Growth, and Cronos Group are three Canadian cannabis companies showing strong potential in July 2025. Each has made strategic moves to expand its U.S. footprint and improve financial health. Tilray offers a diversified portfolio that includes cannabis, beverages, and wellness products. Canopy Growth is focusing on operational efficiency and cost control. Meanwhile, Cronos is delivering revenue growth through product innovation and smart partnerships. As U.S. legalization discussions continue, these Canadian companies are likely to benefit from early positioning. Investors watching the cannabis sector this month should keep a close eye on all three.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
